Indications |
Oral Psychoses Adult: Initially, 20-50 mg daily in 2 divided doses. Increase according to patient response and tolerance over the next 7-10 days to 60-100 mg daily or more, in 2-4 divided doses. Max dose: 250 mg daily. Maintenance dose range: 20-100 mg daily in divided doses. Elderly: 20-60 mg/day. Intramuscular Acute psychosis Adult: Up to 300 mg daily in 2-3 divided doses. Elderly: Reduced dose may be required. |
Contraindications |
Severe CNS depression, coma. |
Warnings / Precautions |
Parkinson's disease. Haemodynamic instability; bone marrow suppression; predisposition to seizures; subcortical brain damage; severe cardiac, hepatic, renal or respiratory impairment. Patients at risk of pneumonia (e.g. Alzheimer's disease). Breast cancer or other prolactin-dependent tumours. Cerebrovascular disease. Decreased GI motility, urinary retention, benign prostatic hyperplasia, xerostomia or visual problems. Narrow-angle glaucoma; myasthenia gravis. May impair ability to drive or operate machinery. Pregnancy and lactation. |
Adverse Reactions |
Arrhythmia, BP changes, orthostatic hypotension, tachycardia, syncope; agitation, ataxia, confusion, dizziness, drowsiness, extrapyramidal symptoms, faintness, headache, insomnia, lightheadedness, seizure, slurred speech, tension; sexual dysfunction, urinary retention; agranulocytosis, leukopenia, thrombocytopenia; muscle weakness; alopecia, dermatitis, photosensitivity, pruritus, rash, seborrhoea; amenorrhoea, irregular menstruation, breast enlargement, galactorrhoea, gynaecomastia; ileus, constipation, nausea, vomiting, polydipsia, wt changes, xerostomia; blurred vision; nasal congestion. Potentially Fatal: Neuroleptic malignant syndrome. |
Overdose Reactions |
Symptoms: Deep sleep, dystonia, agitation, dysrhythmias, extrapyramidal reactions, hypotension, seizures. Management: Symptomatic and supportive. |
Drug Interactions |
Inhibits vasopressor effect of epinephrine. Potentially Fatal: Additive CNS depression with other CNS depressants (e.g. benzodiazepines, barbiturates, alcohol). See Below for More loxapine Drug Interactions |
Lab Interactions |
False-positive tests for phenylketonuria, amylase, uroporphyrins, urobilinogen. |
Food Interactions |
CNS depression may be increased with kava kava, gotu kola, valerian, St John's wort. |
Mechanism of Actions |
Loxapine, a dibenzoxazepine antipsychotic, antagonises central dopaminergic action by blocking postsynaptic mesolimbic D1 and D2 receptors in the brain. It also has serotonin 5-HT2 inhibiting activity. Absorption: Absorbed readily from the GI tract; peak plasma concentrations within 1-2 hr. Distribution: Widely distributed; crosses the placenta and distributes into breast milk. Metabolism: Very rapidly and extensively hepatic. Major metabolites: 7- and 8-hydroxyloxapine. Excretion: Mainly via urine (as conjugated metabolites); via faeces (small amounts as unconjugated metabolites). 12-19 hr (terminal elimination half-life). |
Administration |
Should be taken with food. |
Storage Conditions |
Oral: Store at 20-25°C (68-77°F). |
ATC Classification |
N05AH01 - loxapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics. |
Storage |
Oral: Store at 20-25°C (68-77°F). |
Available As |
|
Loxapine
Post Review about Loxapine Click here to cancel reply.
Loxapine Containing Brands
Loxapine is used in following diseases
Drug - Drug Interactions of Loxapine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.